Overactive Bladder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major overactive bladder markets reached a value of US$ 2.5 Billion in 2023. Looking forward, the publisher expects the 7MM to reach US$ 3.3 Billion by 2034, exhibiting a growth rate (CAGR) of 3.13% during 2023-2034.

The overactive bladder market has been comprehensively analyzed in this report titled "Overactive Bladder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Overactive bladder (OAB) is a medical condition that is characterized by a sudden, uncontrollable urge to urinate. The common symptoms associated with the ailment include a difficult-to-control need to urinate, urinary incontinence, frequent urination, nocturia, etc. Individuals suffering from OAB may also experience disrupted sleep, fatigue, depression, skin problems, infections, etc. This disease can limit a person's work and social interactions, causing a negative impact on their life. The diagnosis of OAB is made by evaluating the medical history, physical exam, and clinical features. Diagnostic tests may include a urine test to rule out infection, a post-void residual (PVR) examination to measure how much urine is left in the bladder after urination, and urodynamic testing to evaluate bladder function. In some cases, various imaging tests, such as an ultrasound or CT scan, may be used to look for structural abnormalities in the bladder or urinary tract. Numerous other diagnostic procedures, including urine workups, bladder ultrasounds, cystoscopies, etc., are also utilized to confirm a diagnosis among patients. Additionally, healthcare professionals may recommend maintaining a bladder diary to better understand the body processes and determine other risk factors that worsen the symptoms.

The increasing prevalence of urinary tract infections, which cause overactivity of the detrusor urinae muscle and involuntary bladder contractions, is primarily driving the overactive bladder market. Furthermore, the rising cases of aging-related cognitive decline that make it challenging for the bladder to comprehend the signals it gets from the brain are also bolstering the market growth. Apart from this, the inflating utilization of effective medications for treating the condition, including antimuscarinics and beta-3 agonists, which can help relax the bladder muscle as well as increase urine retention and emptying capacity, is acting as another significant growth-inducing factor. Moreover, the escalating application of neuromodulation therapy to improve OAB symptoms is further creating a positive outlook for the market. This approach stimulates electrical pulses between the brain neurons and the bladder to ensure normal bladder function. Additionally, the emerging popularity of conservative measures, including lifestyle modification and pelvic floor physical therapy, for managing the condition since they can lower the risk of disease progression, ease symptoms, and improve the quality of life in patients is expected to drive the overactive bladder market in the coming years.

This report provides an exhaustive analysis of the overactive bladder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for overactive bladder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the overactive bladder market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the overactive bladder market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the overactive bladder market

Competitive Landscape:

This report also provides a detailed analysis of the current overactive bladder marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the overactive bladder market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the overactive bladder market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the overactive bladder market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of overactive bladder across the seven major markets?
• What is the number of prevalent cases (2018-2034) of overactive bladder by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of overactive bladder by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with overactive bladder across the seven major markets?
• What is the size of the overactive bladder patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of overactive bladder?
• What will be the growth rate of patients across the seven major markets?

Overactive Bladder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for overactive bladder drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the overactive bladder market?
• What are the key regulatory events related to the overactive bladder market?
• What is the structure of clinical trial landscape by status related to the overactive bladder market?
• What is the structure of clinical trial landscape by phase related to the overactive bladder market?
• What is the structure of clinical trial landscape by route of administration related to the overactive bladder market?

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.